Trading Update and At The Market Facility

Medpal AI PLC

04 December 2025

 

4 December 2025

MedPal AI plc

("MedPal AI" or the "Company")

Trading Update - Pharmacy Operations

MedPal AI Deploys Google's Vertex AI

ATM Facility

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to provide a trading update on its pharmacy operations for November 2025 and also announce that its wholly owned subsidiary, MedPal Limited has deployed Google Cloud's Vertex AI platform on WhatsApp Business. The Directors believe that this makes the MedPal.clinic service, which will be available free to patients 24/7, the first UK registered online pharmacy to integrate advanced AI triage via WhatsApp.  The Company also announces that it has established an At-The-Market (ATM) equity issuance facility through its broker, Clear Capital Markets Limited ("Clear Capital").

Trading Update - Pharmacy Operations

MedPal Limited's pharmacy, MedPal Pharmacy, is now registered with GPhC, with the necessary registration and intellectual property prescription services for certain medications under electronic record systems Patient Group Directions. It also has a Clinical Services team with qualified Independent Prescribers to issue prescriptions and fulfil them.

During November 2025, MedPal Limited processed 28,789 prescription orders through its automated pharmacy operations, with an average item value of £9.72, representing approximately £280,000 of revenue. This represents strong month-on-month growth of more than 90% and demonstrates the increasing demand for the Company's AI-enhanced pharmacy services.

The continued scaling of prescription volumes reflects both the successful integration of the NHS Distance Selling Pharmacy ("DSP") contract and growing uptake of the Company's private weight loss service launched via MedPal.clinic.

Adoption of Vertex AI

MedPal AI has deployed Google's Vertex AI to power intelligent clinical triage through a dedicated WhatsApp Business number (07300 100 600). The Company has built and trained proprietary machine learning models on its clinical data using Google's enterprise AI platform.

The technology delivers sophisticated patient assessment that seamlessly hands over to qualified clinicians for prescribing decisions, combining AI efficiency with clinical safety.

MedPal.clinic now offers patients free 24/7 WhatsApp access to:

·      AI-powered health assessment using Google's Vertex AI;

·      intelligent triage across multiple medical conditions;

·      direct connection to prescribing clinicians when needed; and

·      full medication fulfilment through MedPal's pharmacy operations.

MedPal.clinic's initial focus will be weight-loss treatments including GLP-1 therapies, with the platform designed to expand across additional therapeutic areas such as men's health (including erectile dysfunction and hair loss treatments), women's health (such as hormone replacement therapy and contraception), dermatology (for conditions like acne, psoriasis, and eczema), and respiratory issues (including asthma inhalers and allergy medications). The UK weight-loss treatment market has grown significantly recently with the offer of GLP-1 therapies.

Technology Infrastructure

The service combines two leading technology platforms:

·      Google Cloud Vertex AI: Enables MedPal.clinic to build, train and scale proprietary machine learning models on clinical data; and

·      WhatsApp Business: Provides 24/7 patient access through the UK's most widely used messaging platform.

This integration positions MedPal.clinic as the one of the UK's most technologically advanced online pharmacy operation.

ATM Facility

ATM facilities are common in certain jurisdictions such as the US and Canada, enabling companies to incrementally sell newly issued shares on a stock exchange through a designated broker-dealer at prevailing market prices and on an as-and-when-needed basis.

The Company's recently established online pharmaceutical subsidiary, MedPal Limited, operating MedPal Pharmacy and Medpal.clinic, is experiencing high demand. Additional working capital provided by an ATM would provide flexibility for MedPal Pharmacy to hold greater levels of stock and expand its product line and to undertake marketing campaigns to grow the pharmacy and clinic part of the business more quickly.

On 3 December 2025, the Company entered into an ATM-like facility agreement with Clear Capital (the "Agreement") pursuant to which, Clear Capital will execute sales following receipt of instruction from the Company, via the London Stock Exchange. The aggregate gross proceeds of the facility shall not exceed £2,000,000 and the floor price per ATM Share has been set at 5p. The facility is effective for a period of 24 months, unless terminated earlier pursuant to the Agreement. 

Pursuant to the ATM facility, new ordinary shares in the Company ("ATM Shares") will be made available for sale via the Company's broker on a tranche by tranche basis. Any share sales to be made to the market will be close to the mid-market price at the time and not below a minimum price to be set by the Company for each tranche. Any issuance under the facility will be carried out in a controlled manner and within prudent internal volume parameters, ensuring that sales occur only when market conditions are considered by Clear Capital to be favourable and in a way that supports an orderly market. The Company does not intend to sell ATM Shares in a manner that would place unnecessary pressure on the share price.

Periodically, once an order has been placed under the ATM facility, the Company will issue an RNS to confirm the number of ATM Shares issued, with details of their average sale price and the net proceeds raised by the Company.  Once issued, application for admission to trading on AIM will be sought for each order of ATM Shares. Commission in line with market rates will be retained from the gross proceeds of sales by Clear Capital with the net proceeds being transferred to the Company.

Upon successful completion of the ATM facility, the Company will grant up to 10m warrants to Clear Capital. The precise number of warrants to be issued will depend on the total gross proceeds raised under the facility, calculated in accordance with the terms of the Agreement. No warrants will be issued until completion of the facility. 

The ATM facility may be withdrawn by the Company without notice at any time.

Jason Drummond, CEO of MedPal AI, said:

"We are pleased with MedPal Limited's performance to date, which shows continued strong growth in prescription volumes. Processing nearly 29,000 prescription orders in November 2025 demonstrates the scalability of our automated dispensing infrastructure and validates our integrated healthcare model. The combination of our NHS contract, our state-of-the-art robotic dispensing technology, and AI-powered telehealth services continues to gain traction in the market. In addition, the deployment of Google's Vertex AI platform on WhatsApp Business positions MedPal.clinic as a highly technologically advanced online pharmacy.

"We have built proprietary models with the potential to deliver sophisticated triage at scale whilst maintaining full clinical oversight and we remain focused on sustainable growth. The ATM facility will provide us with flexible funding to accelerate this, to expand our innovative offerings, and meet rising demand, whilst maintaining the highest standards of patient safety and service quality."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts/ Nick Josh	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END